Literature DB >> 8866667

Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response.

A M Soto1, T M Lin, K Sakabe, N Olea, D A Damassa, C Sonnenschein.   

Abstract

Androgens regulate the proliferation of their target cells through a sequential two-step mechanism. In the first step, androgens increase proliferation rates; following this proliferative response, a second step of proliferative shutoff ensues. Human prostate LNCaP cell variants were used to assess whether the proliferative and shutoff effects of androgens could be segregated selectively by manipulating the hormonal milieu. The LNCaP-FGC and LNCaP-LNO cell lines were derived from the same biopsy specimen but exhibited different proliferative responses. Cell proliferation was inhibited by treatment with 10% charcoal-dextran stripped human serum in the LNCaP-FGC variant but not in LNCaP-LNO cells. Physiological androgen concentrations induced a proliferative shutoff in LNCaP-LNO cells (G1 arrest), an effect also expressed by LNCaP-FGC cells. This G1 arrest was irreversible in the LNCaP-FGC variant but was reversed upon androgen withdrawal in LNCaP-LNO cells. A new variant (LNCaP-TJA) was selected from LNCaP-LNO cells treated with 30 nM methyltrienolone for 4 months; these cells proliferated maximally regardless of the presence of androgens. All three cell variants had functional androgen receptors, and androgens induced prostate-specific antigen secretion. The androgen-induced proliferative shutoff in LNCaP-FGC and LNO cells was partially antagonized by antiandrogens and was not mediated by autocrine factors. Finally, the variant LNCaP cell lines described herein are probably representative of phenotypes present in prostate cancer patients during the course of this disease and may arise from selective pressure imposed by therapeutic protocols aimed at modifying the hormonal milieu of the host.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8866667

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  17 in total

Review 1.  Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses.

Authors:  Laura N Vandenberg; Theo Colborn; Tyrone B Hayes; Jerrold J Heindel; David R Jacobs; Duk-Hee Lee; Toshi Shioda; Ana M Soto; Frederick S vom Saal; Wade V Welshons; R Thomas Zoeller; John Peterson Myers
Journal:  Endocr Rev       Date:  2012-03-14       Impact factor: 19.871

2.  Editorial: Centennial Celebration - An Interview With Dr Ana Soto on 25 Years of Research on Endocrine-Disrupting Chemicals.

Authors: 
Journal:  Mol Endocrinol       Date:  2016-08

3.  Data integration, analysis, and interpretation of eight academic CLARITY-BPA studies.

Authors:  Jerrold J Heindel; Scott Belcher; Jodi A Flaws; Gail S Prins; Shuk-Mei Ho; Jiude Mao; Heather B Patisaul; William Ricke; Cheryl S Rosenfeld; Ana M Soto; Frederick S Vom Saal; R Thomas Zoeller
Journal:  Reprod Toxicol       Date:  2020-07-16       Impact factor: 3.143

4.  Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator.

Authors:  P Geck; M V Maffini; J Szelei; C Sonnenschein; A M Soto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

Review 5.  Endocrine disrupting chemicals and disease susceptibility.

Authors:  Thaddeus T Schug; Amanda Janesick; Bruce Blumberg; Jerrold J Heindel
Journal:  J Steroid Biochem Mol Biol       Date:  2011-08-27       Impact factor: 4.292

Review 6.  Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption.

Authors:  Laura N Vandenberg; Maricel V Maffini; Carlos Sonnenschein; Beverly S Rubin; Ana M Soto
Journal:  Endocr Rev       Date:  2008-12-12       Impact factor: 19.871

7.  LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion.

Authors:  Yirong Li; Longgui Wang; Miao Zhang; Jonathan Melamed; Xiaomei Liu; Robert Reiter; Jianjun Wei; Yi Peng; Xuanyi Zou; Angel Pellicer; Michael J Garabedian; Anna Ferrari; Peng Lee
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 8.  The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.

Authors:  Sheng-Qiang Yu; Kuo-Pao Lai; Shu-Jie Xia; Hong-Chiang Chang; Chawnshang Chang; Shuyuan Yeh
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

9.  Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy.

Authors:  C K E Wong; B Namdarian; J Chua; X Chin; R Speirs; T Nguyen; M Fankhauser; J Pedersen; A J Costello; N M Corcoran; C M Hovens
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

10.  Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis?

Authors:  James Robert Krycer; Andrew John Brown
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.